ARASTEP trial evaluates darolutamide plus ADT for high-risk biochemical recurrence of prostate cancer, focusing on radiologic progression-free survival (rPFS) by PSMA PET-CT. The study involves 970 ...

Results of subgroup analyses of the phase 3 CREST trial (NCT04165317) evaluating sasanlimab plus BCG compared with BCG alone ...

"These long-term results continue to support [pembrolizumab's] use as a standard of care for patients at increased risk of recurrence," says Naomi B. Haas, MD.

The relationship between clinical trial results and real-world experience with enzalutamide and darolutamide shows important patterns: The alignment between trial data and clinical experience supports ...

UGN-102's NDA is supported by the phase 3 ENVISION trial, showing a 79.6% complete response rate at 3 months for LG-IR-NMIBC patients. The FDA is evaluating if the observed duration of response is due ...

John Michael DiBianco, MD, discusses findings from the BLUES trial. A recent study evaluated silicone vs polyurethane stents found that the primary outcome of pain intensity and interference at 7 to ...

CT scans remain the most common initial imaging modality for renal mass detection. MRI offers additional sequencing capabilities for better tumor characterization. Ultrasound primarily helps determine ...

A panelist discusses how they would communicate these comparative study results to patients by explaining that both enzalutamide and darolutamide effectively control metastatic prostate cancer when ...

The study was published in JCO Oncology Practice. “I think 1 thing that people might hypothesize is that the lower citation rates of women-women papers may be due to less female physicians in these ...

Amy E. Krambeck, MD, recaps her talk from AUA 2025. She began by highlighting the wealth of options for benign prostatic hyperplasia (BPH), emphasizing the need for clinicians to be strategic in their ...

Robotic prostate surgery and resource use: When prostate surgery is performed robotically, the patient typically requires a catheter for about 1 week. This leads to increased resource utilization, ...